{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Herrmann J"],"funding":["Foundation Leducq Network of Excellence in Cardio-Oncology","Longer Life Foundation and Children’s Discovery Institute","Austrian Science Fund FWF","British Heart Foundation","National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant","NHLBI NIH HHS","Miami Heart Foundation/Research Institute","CIHR","National Institutes of Health/National Heart, Lung, Blood Institute","National Institutes of Health/National Cancer Institute","a Canada Research Chair in Cardiooncology and the Canadian Institutes of Health Research","Austrian Science Fund (FWF) Herzfelder'sche Familienstiftung","NCI NIH HHS","Gelb Master Clinician Award and Catherine Fitch Geoff Fund at Brigham and Women’s Hospital"],"pagination":["280-299"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8803367"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(4)"],"pubmed_abstract":["The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the m"],"journal":["European heart journal"],"pubmed_title":["Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement."],"pmcid":["PMC8803367"],"funding_grant_id":["R01HL137562","PG/19/64/34434","137132 and 142456","P30 CA008748","R01CA233601","R01 HL130539","P30627-B25","P30 CA014236","R01 CA233610","K24HL150238","R01 CA233601","R01 HL137562","R01HL130539","142456","K24 HL150238","137132","P 30625"],"pubmed_authors":["Cardinale D","Reynolds KL","Fradley MG","Lenihan D","Liu JE","Lang NN","Ganatra S","Minotti G","Ky B","Curigliano G","Valent P","Dent S","Barac A","Herrmann J","Lyon AR","Blaes A","Thavendiranathan P","Lopez-Fernandez T","Pusic I","Mitchell JD","O'Quinn R","Armenian S","Carver J","Nohria A","Porter C","Neilan TG","Ruddy KJ"],"additional_accession":[]},"is_claimable":false,"name":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.","description":"The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the m","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T22:15:21.966Z","creation":"2025-04-04T22:15:21.966Z"},"accession":"S-EPMC8803367","cross_references":{"pubmed":["34904661"],"doi":["10.1093/eurheartj/ehab674"]}}